New antibody drug targets immune system to fight advanced cancers
NCT ID NCT05614258
First seen Jan 10, 2026 · Last updated May 08, 2026 · Updated 16 times
Summary
This early-phase study tests a new drug called ADG206 in people with advanced solid tumors that have not responded to standard treatments. ADG206 is designed to activate the immune system to attack cancer cells. The main goals are to check safety, find the right dose, and see how the body responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ashford Cancer Centre Research
Kurralta Park, South Australia, 5037, Australia
-
Monash Health
Clayton, Victoria, 3168, Australia
Conditions
Explore the condition pages connected to this study.